{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:51:04Z","timestamp":1787028664647,"version":"build-2736575974"},"reference-count":39,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Direct-acting antivirals (DAAs) have revolutionized the management of chronic hepatitis C virus (HCV) infection. However, real-world data on the effectiveness and safety of DAA therapy in patients with history orthotopic liver transplantation (OLTx) remain limited. This study aimed to evaluate the clinical characteristics, effectiveness, and safety of DAA therapy in liver transplant recipients with chronic hepatitis C in a nationwide, real-world cohort. Methods: A retrospective analysis was performed of all consecutive adult patients who underwent OLTx before starting DAA therapy between July 2015 and December 2024 within the EpiTer-2 project, which included 20,586 patients treated because of chronic hepatitis C. Results: A total of 141 patients participated in the study, with most of them being men (66%) and aged 50 years or older. Most patients (80%) had comorbidities, and nearly a quarter of the population had cirrhosis of the transplanted liver at the start of antiviral therapy. The median time from OLTx to initiation of antiviral therapy was 24 months. Overall, SVR was achieved in 96.4% of patients in the intention-to-treat analysis and in 98.6% after excluding patients lost to follow-up. The treatment was well tolerated. Serious adverse events were reported in five patients. During DAA treatment and 12 weeks of follow-up after treatment, two deaths were reported. Subgroup analysis by time from OLTx to antiviral therapy (\u226424 vs. &gt;24 months) revealed no differences in effectiveness and safety despite some baseline clinical variations. Conclusions: DAA therapy in liver transplant recipients with chronic HCV infection is highly effective and well-tolerated.<\/jats:p>","DOI":"10.3390\/jcm15010346","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T11:11:46Z","timestamp":1767352306000},"page":"346","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment with Direct-Acting Antivirals in Patients with HCV Infection After Liver Transplantation"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-9230","authenticated-orcid":false,"given":"Micha\u0142","family":"Brzd\u0119k","sequence":"first","affiliation":[{"name":"Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland"},{"name":"Department of Gastroenterology, Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-1084","authenticated-orcid":false,"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Allergology, Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-5324","authenticated-orcid":false,"given":"Olga","family":"Tronina","sequence":"additional","affiliation":[{"name":"Lazarski University, 02-662 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Laurans","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, 70-204 Szczecin, Poland"},{"name":"Multidiscyplinary Voivodship Hospital, 66-400 Gorz\u00f3w Wlkp, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-4603","authenticated-orcid":false,"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[{"name":"ID Clinic, 41-400 Mys\u0142owice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-8519","authenticated-orcid":false,"given":"Dorota","family":"Dybowska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 85-030 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3815-3745","authenticated-orcid":false,"given":"Anna","family":"Parfieniuk-Kowerda","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 15-540 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-5432","authenticated-orcid":false,"given":"Magdalena","family":"Tudrujek-Zdunek","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Bia\u0142kowska-Warzecha","sequence":"additional","affiliation":[{"name":"Biega\u0144ski Regional Specjalist Hospital, 91-347 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Janocha-Litwin","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Hepatology Clinic, Medical University of Wroclaw, 50-367 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-1635","authenticated-orcid":false,"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 15-540 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"ref_1","unstructured":"(2025, October 02). Hepatitis C. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural History of Hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Flisiak, R., Zar\u0119bska-Michaluk, D., Janczewska, E., \u0141api\u0144ski, T., Rogalska, M., Karpi\u0144ska, E., Miku\u0142a, T., Bolewska, B., Bia\u0142kowska, J., and Flejscher-St\u0119pniewska, K. (2021). Five-Year Follow-up of Cured HCV Patients under Real-World Interferon-Free Therapy. Cancers, 13.","DOI":"10.3390\/cancers13153694"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102443","DOI":"10.1016\/j.jiph.2024.04.027","article-title":"Global Mortality of Chronic Liver Diseases Attributable to Hepatitis B Virus and Hepatitis C Virus Infections from 1990 to 2019 and Projections to 2030","volume":"17","author":"Ou","year":"2024","journal-title":"J. Infect. Public Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1016\/S2468-2667(23)00149-4","article-title":"Hepatitis B and C in Europe: An Update from the Global Burden of Disease Study 2019","volume":"8","author":"Cortesi","year":"2023","journal-title":"Lancet Public Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ajt.16978","article-title":"OPTN\/SRTR 2020 Annual Data Report: Liver","volume":"22","author":"Kwong","year":"2022","journal-title":"Am. J. Transpl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.14218\/JCTH.2017.00007","article-title":"Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-Acting Antiviral Agents","volume":"5","author":"Cholankeril","year":"2017","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-Related Fibrosis Progression Following Liver Transplantation: Increase in Recent Years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_9","first-page":"211","article-title":"Hepatitis C and Liver Transplantation","volume":"13","author":"Tsoulfas","year":"2009","journal-title":"Hippokratia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/01.TP.0000101738.27552.9D","article-title":"Long-Term Outcome of Liver Transplants for Chronic Hepatitis C: A 10-Year Follow-Up","volume":"77","author":"Neumann","year":"2004","journal-title":"Transplantation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/lt.20157","article-title":"Outcomes of Acute Rejection after Interferon Therapy in Liver Transplant Recipients","volume":"10","author":"Saab","year":"2004","journal-title":"Liver Transpl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus after Liver Transplantation: A Review and Quantitative Analysis","volume":"6","author":"Wang","year":"2006","journal-title":"Am. J. Transpl."},{"key":"ref_13","first-page":"1","article-title":"Antiviral Treatment for Hepatitis C Virus Infection after Liver Transplantation","volume":"2010","author":"Sugawara","year":"2010","journal-title":"Hepat. Res. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3748\/wjg.v29.i6.949","article-title":"Decade of Optimizing Therapy with Direct-Acting Antiviral Drugs and the Changing Profile of Patients with Chronic Hepatitis C","volume":"29","author":"Invernizzi","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in Hepatitis C Research: From Discovery to Cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on Liver Transplantation: Major Effects on the Evolution of Indications and Results. An ELITA Study Based on the ELTR Registry","volume":"69","author":"Belli","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/tri.12896","article-title":"Efficacy and Safety of Simeprevir and Sofosbuvir with and without Ribavirin in Subjects with Recurrent Genotype 1 Hepatitis C Postorthotopic Liver Transplant: The Randomized GALAXY Study","volume":"30","author":"Fontana","year":"2017","journal-title":"Transpl. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/ctr.12634","article-title":"Sofosbuvir plus Simeprevir Treatment of Recurrent Genotype 1 Hepatitis C after Liver Transplant","volume":"29","author":"Punzalan","year":"2015","journal-title":"Clin. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/lt.24366","article-title":"Interferon-Free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real-World Experience from the Hepatitis C Therapeutic Registry and Research Network","volume":"22","author":"Brown","year":"2016","journal-title":"Liver Transpl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and Sofosbuvir plus Ribavirin in Patients with Genotype 1 or 4 Hepatitis C Virus Infection and Advanced Liver Disease: A Multicentre, Open-Label, Randomised, Phase 2 Trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12072-016-9778-6","article-title":"Ledipasvir\/Sofosbuvir without Ribavirin Is Effective in the Treatment of Recurrent Hepatitis C Virus Infection Post-Liver Transplant","volume":"11","author":"Shoreibah","year":"2017","journal-title":"Hepatol. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series\u2606","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2023.125957","article-title":"Recommendations of the Polish Group of Experts for HCV for the Treatment of Hepatitis C in 2023","volume":"9","author":"Tomasiewicz","year":"2023","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on Non-Invasive Tests for Evaluation of Liver Disease Severity and Prognosis\u20142021 Update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature04083","article-title":"Hepatitis C and Liver Transplantation","volume":"436","author":"Brown","year":"2005","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105899","DOI":"10.4254\/wjh.v17.i6.105899","article-title":"Sex-Related Differences in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Drugs","volume":"17","author":"Dobrowolska","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijsu.2020.01.145","article-title":"Liver Transplantation for Hepatitis C Patients in the Era of Direct-Acting Antiviral Treatment: A Retrospective Cohort Study","volume":"75","author":"Khan","year":"2020","journal-title":"Int. J. Surg."},{"key":"ref_28","first-page":"637","article-title":"Management of Recurrent Hepatitis C Following Liver Transplantation","volume":"6","author":"Gonzalez","year":"2010","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5114\/ceh.2016.63870","article-title":"Efficacy of HCV Treatment in Poland at the Turn of the Interferon Era\u2014the EpiTer Study","volume":"4","author":"Flisiak","year":"2016","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"206302","DOI":"10.1155\/2015\/206302","article-title":"Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis","volume":"2015","author":"Chen","year":"2015","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1600-6143.2008.02362.x","article-title":"Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection","volume":"8","author":"Veldt","year":"2008","journal-title":"Am. J. Transpl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e15050","DOI":"10.1111\/ctr.15050","article-title":"Progression of Fibrosis in Liver Transplant Recipients with Hepatitis C before and after Sustained Virologic Response","volume":"37","author":"Liu","year":"2023","journal-title":"Clin. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.29258","article-title":"Safety and Efficacy of Current Direct-acting Antiviral Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study","volume":"66","author":"Saxena","year":"2017","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e13047","DOI":"10.1111\/tid.13047","article-title":"Direct-acting Antiviral Agents for Liver Transplant Recipients with Recurrent Genotype 1 Hepatitis C Virus Infection: Systematic Review and Meta-analysis","volume":"21","author":"Liu","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1002\/jmv.26383","article-title":"Decompensated Cirrhosis and Liver Transplantation Negatively Impact in DAA Treatment Response: Real-world Experience from HCV-LALREAN Cohort","volume":"92","author":"Ridruejo","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., Re, V.L., the American Association for the Study of Liver Diseases-Infectious Diseases Society of America HCV Guidance Panel, Heald, J., Demisashi, G., Durzy, E., Davis-Owino, A., and Tynes, S. (2023). Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases\u2014Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis., ciad319.","DOI":"10.1093\/cid\/ciad319"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5114\/ceh.2017.71483","article-title":"Accelerated Hepatocellular Carcinoma Recurrence Rate after Postoperative Direct-Acting Antivirals Treatment\u2014Preliminary Report","volume":"4","author":"Jonas","year":"2017","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/ajt.13111","article-title":"Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered with ABT-450, Ombitasvir, and Dasabuvir","volume":"15","author":"Badri","year":"2015","journal-title":"Am. J. Transpl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e12972","DOI":"10.1111\/tid.12972","article-title":"Safety and Effectiveness of Direct Acting Antivirals for Treatment of Hepatitis C Virus in Patients with Solid Organ Transplantation","volume":"20","author":"Mansour","year":"2018","journal-title":"Transpl. Infect. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/1\/346\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:12:09Z","timestamp":1767611529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/1\/346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15010346"],"URL":"https:\/\/doi.org\/10.3390\/jcm15010346","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}